Civil Procedure Health Intellectual Property

Patents Pharmaceutical Patents Pharmaceutical Industry Patent Infringement Patent Litigation FDA Biosimilars Appeals BPCIA Patent-Eligible Subject Matter Amgen Generic Drugs SCOTUS Apotex Canada Popular Prescription Drugs Sandoz v Amgen Teva Pharmaceuticals ANDA Healthcare Life Sciences Health Canada Medical Devices Patent Invalidity PMNOC Regulations Sandoz Supreme Court of Canada Biotechnology Commercial Marketing DNA Obviousness Patent Dance Preliminary Injunctions USPTO AstraZeneca Biologics Health Care Providers Hospira Motion to Dismiss Patent Trial and Appeal Board Trademarks Australia CETA Clinical Trials CLS Bank v Alice Corp Eli Lilly Hatch-Waxman Lanham Act Mayo v. Prometheus Myriad Notice Requirements Patented Medicines Summary Judgment Abbott Laboratories AMP v Myriad Breach of Contract CADTH Damages Dismissals Hospitals Inter Partes Review (IPR) Proceeding Janssen Pharmaceuticals Leave to Appeal Merck Motion To Strike Myriad-Mayo Patent Applications Patented Medicine Prices Review Board (PMPRB) Pay-For-Delay Pfizer Prior Art Product of Nature Doctrine Public Health Reversal Reverse Payment Settlement Agreements Section 101 The Patent Act Trade Secrets Trademark Infringement Arbitration Bilski Biologics Price Competition and Innovation Act of 2009 Certiorari Chemicals Claim Construction Class Action Competition Authorities Declaratory Judgments Diagnostic Method Diagnostic Tests Divided Infringement Double Patent Drug Approvals En Banc Review EU Evidence False Claims Act (FCA) First-to-File Fracking FTC FTC v Actavis Genetic Materials GlaxoSmithKline Health Information Technologies Hearsay HIV Human Genes Imports Indirect Infringement Intellectual Property Protection Inventors Judicial Review Manufacturers Mental Health Mootness New Guidance Non-Disclosure Agreement Noninfringement Patent Ownership Patent-in-Suit Permanent Injunctions Petition for Writ of Certiorari Pharmacies Pleadings Preemption Product Labels Public Consultations Reaffirmation Safe Harbors Section 8 Trade Dress Unfair Competition Utility Patents Vaccinations AbbVie Abstract Ideas Accounting Administrative Procedure Act Administrative Proceedings Admissible Evidence Affordable Care Act AIDS Akamai Technologies Allergan Inc America Invents Act Amgen v Apotex Amicus Briefs Antitrust Litigation Antitrust Violations App Developers Ariosa Attorney's Fees Balancing Test Bayer Bayh-Dole Act Boston Scientific BRCA Burden of Proof Business Court Division Business Records Cancer Celltrion Chevron Deference Children's Hospital Chiropractors CIGNA Classen Immunotherapies Clear Error Standard Clinical Laboratory Testing Code of Conduct Collateral Order Doctrine Component Parts Doctrine Compulsory Licenses Computer-Related Inventions Confidential Information Confidentiality Agreements Consultants Copyright Infringement Counterfeit Goods Regulation Covenant of Good Faith and Fair Dealing Creditors Cross-Border Transactions Cuozzo Speed Technologies v Lee CVS Data Protection De Novo Standard of Review Declaratory Rulings Department of Health Department of Veterans Affairs Depositions Digital Health Direct Infringement Disability Benefits Disclosure Requirements Discovery Discrimination Drug Distribution Drug Pricing Drug Testing E-Commerce Elan Pharmaceuticals Electronic Filing Employment Contract Energy Sector Environmental Policies Extraterritoriality Rules False Implied Certification Theory FCRA FDA Approval FDCA Federal Contractors Federal Rule 12(b)(6) Federal Rules of Civil Procedure FFDCA Filing Deadlines Final Guidance First Sale Doctrine Flood Insurance Food & Drug Regulations Forest Laboratories Fraud Free Trade Agreements Functionality Genentech Germany Gilead Sciences Gray Market Goods Grey Market Health Insurance Health IT Hearsay Exceptions IBM Imminent Harm Implied Certification Inducement Inevitable Disclosure Doctrine Infringement Injunctive Relief Innovation Insurance Industry Interim Guidance International Litigation IP License Joint Infringement Joint Venture Judgment Creditors Judgment on the Pleadings Kaiser Permanente Kappos Kia Kingdomware Techs. Inc. v United States Kirtsaeng v. John Wiley & Sons Labeling Legislative Agendas Licenses Life Technologies Corp v Promega Corp Likelihood of Confusion Limelight Limelight v Akamai Loans Lost Profits Machine-or-Transformation Test Mandamus Petitions Mandatory Disclosure Rules Manufacturer Liability Marketing Exclusivity Periods Materiality Medicaid Medical Malpractice Medical Marijuana Medical Reports Medical Research Medicare Mergers Method Claims Misappropriation Misleading Statements Motion for Leave Motion To Intervene Myriad v Ambry Natural Gas Nestle New Legislation Nexium NIH No-AG Agreement Non-Compete Agreements Non-Solicitation Agreements Novartis NRDC Oil & Gas On-Sale Bar Opioid Orphan Drugs Otsuka Pharmaceutical OxyContin Patent Examinations Patent Terms Patent Validity Patient Privacy Rights Personal Care Products Personal Jurisdiction Personalized Medicine Petition For Rehearing Physicians Prior User Privacy Laws Product Exclusivity Product Hopping Property Owners Proposed Amendments Proposed Legislation Proposed Regulation Public Comment Public Use Regeneron Remand Reverse Payments Ripeness Rule of Two Safeway Inc Samsung Bioepis Sanofi Scientific Research Section 1983 Sequenom Set-Asides Settlement Sherman Act Shire Development v Watson Software Software Developers Standard of Review Standing State Law Claims Stays Stem cells Strategic Planning Supplementary Protection Certificate Supply Agreements Technical Errors Technology Telehealth The Copyright Act Third-Party Trademark Litigation Trademark Ownership Trans-Pacific Partnership Trials UK Unauthorized Access Universal Health Services Inc v United States ex rel Escobar University of California Unjust Enrichment Unlicensed Medical Providers VOSB Warning Labels Whistleblowers Willful Infringement